Work

Targeting insulin feedback to enhance alpelisib (TIFA): A phase II randomized trial in metastatic, PIK3CA-mutant, hormone receptor–positive breast cancer.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps1113

Authors: Sherry Shen, Erica Salehi, Azeez Farooki, James Flory, Dominiq Williams, Andrea Carpio, Cassandra Chang, Mario E. Lacouture, Eleni Andreopoulou, Sagar D. Sardesai, Komal L. Jhaveri, Lewis Clayton Cantley, Marcus D. Goncalves, Neil M. Iyengar

Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, NewYork–Presbyterian Hospital

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281770265

Cites:

Cited by: 3

Related to: 10